1
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
13138
Neoplasms
10481
Carcinoma, Non-Small-Cell Lung
6874
Prostatic Neoplasms
6268
Colorectal Neoplasms
5948
Lung Neoplasms
5105
Multiple Myeloma
3577
Pancreatic Neoplasms
3563
Leukemia, Myeloid, Acute
3510
Neoplasm Metastasis
3508
Carcinoma, Hepatocellular
3273
Ovarian Neoplasms
3168
Melanoma
3141
Stomach Neoplasms
3057
Lymphoma
2983
Head and Neck Neoplasms
2604
Recurrence
2557
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2499
Leukemia
2362
Colonic Neoplasms
2328
Brain Neoplasms
2313
Lymphoma, Non-Hodgkin
2269
Rectal Neoplasms
2192
Uterine Cervical Neoplasms
2191
Glioblastoma
2016
Leukemia, Lymphocytic, Chronic, B-Cell
1992
Carcinoma, Renal Cell
1913
Squamous Cell Carcinoma of Head and Neck
1880
Lymphoma, Follicular
1848
Esophageal Neoplasms
1801
Interventions
darolutamide
2
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Biochemically Recurrent Prostate Cancer
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts